GENE ONLINE|News &
Opinion
Blog

2022-07-07| ChinaCOVID-19

Brii Biosciences Begins Marketing COVID-19 Antibody Cocktail Therapy in China

by Fujie Tham
Share To

China and US-headquartered Brii Biosciences announced the commercial marketing of the amubarvimab/romlusevimab combination therapy for COVID-19 in China. The company announced the release of the first commercial antibodies batch on July 7 after the initial December 2021 conditional approval by China’s National Medical Products Administration (NMPA).

In March 2022, National Health Commission of China added Brii’s antibody combination to its COVID-19 treatment guideline, officially recommending the drug for treatments. At the same time, China’s regulator has rubber-stamped AstraZeneca’s Evusheld antibody combination for use in a special medical tourism zone in Qionghai. 

Related article: Brii Bio’s Covid-19 Antibody Cocktail Gets the Greenlight in China 

 

Brii’s Combination Demonstrated Efficacy in ACTIV-2 Phase 3 Study

 

The amubarvimab plus romlusevimab combination are neutralizing antibodies derived and engineered from recovered COVID-19 patients from Shenzhen’s 3rd People’s Hospital, Brii said the combination is enhanced to “more durable treatment effect”.

In the ACTIV-2 Phase 3 clinical trial, the US National Institute of Allergy and Infectious Diseases (NIAID) found the company’s antibody combination showed an 80% reduction in hospitalizations and deaths, and improved safety outcomes in high-risk non-hospitalized patients. The therapy works for patients that are treated early or late with similar efficacy rates, making it a good asset for mild and moderate COVID-19 patients at risk of developing severe conditions. 

Brii’s therapy fared well against all major COVID-19 variants of concern, including Omicron subvariants BA.1.1 and BA.2.

While in the US, Brii Biosciences’ Emergency Use Authorization (EUA) application for the amubarvimab/romlusevimab combination is under review by the FDA and is pending satisfactory completion of FDA inspection of its manufacturing partners.

“As a startup multi-national biotech company co-located in both China and the US, we are working to advance access to this treatment for a broad range of COVID-19 patients in China, while also scaling its effort to match the need for COVID-19 treatment options to combat the pandemic,”said Rogers Luo, President of Brii Bio Greater China.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
AstraZeneca Invests $26.5 Million in New Production Line for Diabetes Drug in China
2024-01-19
JPM 2024: AZ, Ginkgo and Moderna Provides Business Updates, Illustrating Optimistic Prospects
2024-01-11
AstraZeneca’s severe asthma drug Tezspire has been granted market authorization in South Korea
2023-12-25
LATEST
Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
2024-02-26
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
2024-02-21
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
2024-02-21
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
2024-02-21
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
2024-02-19
EVENT
Scroll to Top